Last reviewed · How we verify
Burkitt's lymphoma
Approved treatments
- Oncovin · University of Colorado, Denver
- Vincristin · Arbeitsgemeinschaft medikamentoese Tumortherapie
- Mabthera · Roche
- Decadron · Generic (originally Merck)
- adriacin · Chipscreen Biosciences, Ltd.
- Hydroxydaunorubicin · University of Colorado, Denver
- Cyclophosphamid · Zhejiang University
- Cytoxan (Lyophilized) · Baxter
Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites. - Oncovin · Pfizer Inc.
- Oncovin · Pfizer Inc.
- Mabthera · Roche
Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC. - Mabthera · Roche
Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction. - Liposomal Doxorubicin · Pfizer
- Doxorubicin Hydrochloride · Pfizer
Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division. - Cytoxan (Lyophilized) · Baxter
Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells. - Trexall · Generic (originally Lederle Laboratories)
Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune). - Methotrexat · Biocad
- Hydroxydaunomycin · Weill Medical College of Cornell University
- Adriamycin · Johann Wolfgang Goethe University Hospital
Clinical guidelines
- FDA label — 1L
Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Burkitt's lymphoma. - FDA label — 1L
Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in diffuse non-Hodgkin's lymphoma, large cell. - FDA label — 1L
Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in follicular non-Hodgkin's lymphoma. - FDA label — 1L
Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease. - FDA label — 1L
Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in nephroblastoma. - FDA label — 1L
Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in neuroblastoma. - FDA label — 1L
Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in non-Hodgkin's lymphoma. - FDA label — 1L
Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in rhabdomyosarcoma.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Burkitt's lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- Burkitt's lymphoma treatment landscape brief
- Burkitt's lymphoma treatment updates RSS
Frequently asked questions about Burkitt's lymphoma
What drugs treat Burkitt's lymphoma?
Tracked treatments include Oncovin, Vincristin, Mabthera, Decadron, adriacin, Hydroxydaunorubicin, Cyclophosphamid, Cytoxan (Lyophilized).
What is the treatment for Burkitt's lymphoma?
Standard treatment for Burkitt's lymphoma includes Oncovin, Vincristin, Mabthera, Decadron, adriacin. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Burkitt's lymphoma?
FDA label publishes guidelines for Burkitt's lymphoma. 8 guideline references tracked.
Related
- Treatment landscape: Burkitt's lymphoma patent cliff · Burkitt's lymphoma CI report
- Treatment: Oncovin · University of Colorado, Denver
- Treatment: Vincristin · Arbeitsgemeinschaft medikamentoese Tumortherapie
- Treatment: Mabthera · Roche
- Treatment: Decadron · Generic (originally Merck)
- Treatment: adriacin · Chipscreen Biosciences, Ltd.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing